
Opinion|Videos|February 4, 2025
Navigating Therapies for BCG-Unresponsive NMIBC: Immunotherapies and Chemotherapies
Experts discuss the evolving landscape of chemotherapy and immunotherapy options for patients with non-muscle invasive bladder cancer (NMIBC).
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5











